| Document |
Document Title |
|
WO/2006/062224A1 |
An SGLT inhibitor comprising a compound of the formula: (&Verbar ) wherein the ring A is an optionally substituted ring; R1 is an optionally substituted hydrocarbon group, etc.; each of R2 and R3 independently is a hydrogen atom, an opti...
|
|
WO/2006/062093A1 |
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...
|
|
WO/2006/054652A1 |
An FAAH inhibitor; and a preventive/therapeutic agent for cerebrovascular disorders and a preventive/therapeutic agent for sleep disorders which each contains the inhibitor. The FAAH inhibitor is a compound represented by the formula (I0...
|
|
WO/2006/050830A1 |
The invention relates to substituted benzoylguanidines of formula (I), where R1 to R8, X and Y have the meanings given in the claims and the pharmaceutically-acceptable salts thereof which are substituted acylguanidines and inhibit cellu...
|
|
WO/2006/051704A1 |
An imine compound represented by the formula (X) (wherein A represents a heterocyclic group; R1, R2, and R3 each represents hydrogen, halogeno, C1-10 alkyl optionally substituted by haloaryl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-10 alkox...
|
|
WO/2006/044456A1 |
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particu...
|
|
WO/2006/034315A2 |
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R...
|
|
WO/2006/030211A2 |
Compounds of formula: (I) are found to antagonise N-type calcium channels wherein: - A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C3-C6 carbocycl...
|
|
WO/2006/028970A1 |
Provided herein are compounds and compositions for modulation of tyrosine phosphatase activity. In one embodiment, compounds and compositions for inhibiting protein tyrosine phosphatase activity are provided. In another embodiment, provi...
|
|
WO/2006/019020A1 |
Urea derivatives having excellent DGAT inhibiting activity or pharmacologically acceptable salts thereof, namely, urea derivatives represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R1 is C6...
|
|
WO/2006/014413A1 |
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheros...
|
|
WO/2006/014134A1 |
Compounds of formula: (chemical formula to be inserted here - please see paper copy) wherein Ar1 is as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepar...
|
|
WO/2006/015004A2 |
A white light-emitting electroluminescent device having an emissive layer that includes a green light-emitting compound and a red light-emitting compound dispersed in a blue light-emitting host.
|
|
WO/2006/014357A1 |
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheros...
|
|
WO/2006/010751A1 |
The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative ...
|
|
WO/2006/008196A1 |
The present invention relates to a process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates of compounds having at least a hydroxyl or thiol functional group, according to the following ...
|
|
WO/2006/009134A1 |
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...
|
|
WO/2006/010082A1 |
In general, the present invention relates to compounds capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and meth...
|
|
WO/2006/002284A1 |
This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of...
|
|
WO/2005/121110A1 |
Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-li...
|
|
WO/2005/118575A1 |
The invention relates to compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptas...
|
|
WO2005058298B1 |
The present invention provides FK228 analogs and methods of making and using the same. Such analogs are potent inhibitors of histone deacetylase and, in certain embodiments, are capable of specifically targeting cancerous cells and tissu...
|
|
WO/2005/115995A1 |
An amine compound having a specific structure; and an organic electroluminescent element which comprises an anode and a cathode and, sandwiched therebetween, an organic thin film layer consisting of one or more layers comprising at least...
|
|
WO/2005/113527A1 |
The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula (I) wherein R1, R2 and R6 are as defined herein, X is CH2 or O, A is a group of the formula (G1, G2, G2a, G3, G4, G5 or G...
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/105764A1 |
Compounds of the formula (I): in which R, R1 and R2 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and . processes for the...
|
|
WO/2005/103020A1 |
The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as...
|
|
WO/2005/100305A1 |
The present invention is directed to a new class of 4-cyano-phenoxy-alkyl carboxyl derivatives and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess...
|
|
WO/2005/097817A2 |
The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another...
|
|
WO/2005/097117A1 |
Provided are thiadiazolidine compounds of Formula (I) wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a -C(O)- and comprising at least an aromatic ring, and their...
|
|
WO/2005/095334A1 |
The present invention relates to compounds of the Formula (I), wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical com...
|
|
WO/2005/095368A1 |
The present invention relates to compounds of the Formula (I) wherein R1, R3, R5, R7, X, Y and U are as defined. Compounds of the Formula (I) have activity inhibiting production of Aß-peptide. The invention also relates to pharmaceutica...
|
|
WO/2005/092836A1 |
A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7.including R3', p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for t...
|
|
WO/2005/092099A1 |
Bicyclic uracils and related compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the compounds are of Formula (I) wherein a, b, Y, R1, R2, R3 and R4 are defined herein. The compounds are useful...
|
|
WO/2005/092304A2 |
Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents, wherein: R1, R2 and R3 are as defined herein. Certain compounds of formula (I) are also provided. Compound...
|
|
WO/2005/092845A1 |
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists...
|
|
WO/2005/092873A2 |
The invention discloses a new compounds as per general formula (I): where -R stands for: alkyl, alkenyl, aryl, substituted aryl (with chlorine, alkyl, alkoxyl, -CF3, CN, -NO2), phenoxyphenyl, or morpholinoalkyl. The new compounds are app...
|
|
WO/2005/090297A1 |
The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC is -NR1R2, RA is a group having the formula (A), (B) or (C) RB is h...
|
|
WO/2005/090298A1 |
The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC forms together with the phenyl ring to which it is attached a benzo...
|
|
WO/2005/087752A2 |
The invention relates to novel aminoalkanol derivatives and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disord...
|
|
WO/2005/085220A1 |
The invention relates to the use of compounds of formula (I) where Art, Ar2 and Z have the meanings given in claim 1, for the prophylaxis and/or treatment of diseases in which the inhibition, regulation and/or modulation of signal transd...
|
|
WO/2005/082874A1 |
It is intended to provide a drug useful as a remedy and a preventive for hyperlipemia; a drug also useful as a remedy and a preventive for liver disorders accompanying bile stasis, in particular, primary biliary cirrhosis, primary sclero...
|
|
WO/2005/082871A2 |
The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of ...
|
|
WO/2005/080362A1 |
E-cinnamic amides of piperazine derivatives according to formula (I) wherein X is chloro or Fluor and R1 is an aromatic or heteroaromatic group. Their pharmaceutically acceptable salts, pharmaceutical compositions containing them and the...
|
|
WO/2005/080360A1 |
Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from -C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linke...
|
|
WO/2005/077925A1 |
Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure of formulae (I) or (II); whereinR1 is hydrogen (H), alkyl or substitute...
|
|
WO/2005/077124A2 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
|
|
WO/2005/075435A1 |
The present invention relates to modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'), compositions thereof, and methods therewith. The prese...
|
|
WO/2005/072731A1 |
Compounds of formula (I) are provided as well as compositions and methods of using compounds of formula (I) for modulating the activity of the estrogen-related receptors and for the treatment, prevention, or amelioration of one or more s...
|
|
WO/2005/068413A1 |
A novel amine compound utilizable as a hole-transporting or hole-injecting material in organic electroluminescent elements, electrophotographic photoreceptors, etc. The novel amine compound is represented by the following general formula...
|
